BACKGROUND: Neonatal seizures are associated with adverse neurologic sequelae including epilepsy in childhood. Here we aim to determine whether levels of cytokines in neonates with brain injury are associated with acute symptomatic seizures or remote epilepsy. METHODS: This is a cohort study of term newborns with encephalopathy at UCSF between 10/1993 and 1/2000 who had dried blood spots. Maternal, perinatal/postnatal, neuroimaging, and epilepsy variables were abstracted by chart review. Logistic regression was used to compare levels of cytokines with acute seizures and the development of epilepsy. RESULTS: In a cohort of 26 newborns with neonatal encephalopathy at risk for hypoxic ischemic encephalopathy with blood spots for analysis, diffuse alterations in both pro-and anti-inflammatory cytokine levels were observed between those with (11/28, 39%) and without acute symptomatic seizures. Seventeen of the 26 (63%) patients had >2 years of follow-up and 4/17 (24%) developed epilepsy. Higher levels of pro-inflammatory cytokines IL-6 and TNF-α within the IL-1β pathway were significantly associated with epilepsy. CONCLUSIONS: Elevations in pro-inflammatory cytokines in the IL-1β pathway were associated with later onset of epilepsy. Larger cohort studies are needed to confirm the predictive value of these circulating biomarkers.
INTRODUCTION
Neonatal seizures are an indicator of neurologic dysfunction with an incidence of 2.8-4.4/1000 live births. 1, 2 Neonates with seizures are at high risk for a range of adverse neurologic sequelae compared to those without seizures, with up to 25% developing remote epilepsy. 3, 4 Risk factors for epilepsy include severity of encephalopathy, severity and type of brain injury, abnormal electroencephalogram (EEG) background, and seizure frequency. [3] [4] [5] Together these variables can identify a high-risk group with an approximately 50% chance of developing epilepsy. [3] [4] [5] Additional predictors of epilepsy, however, are needed in order to improve stratification, to better inform families, and to guide therapeutic studies that can alter epilepsy outcomes. 6, 7 Alterations in the levels of inflammatory cytokines, in particular the IL-1β pathway, may serve as biomarkers of neurologic disease. These molecules are secreted by activated neuroglia often within an hour of an inciting central nervous system (CNS) insult, including status epilepticus, stroke, and infection. [8] [9] [10] IL-1β activates its endogenous receptor with resultant increases in neuronal excitability. [11] [12] [13] After an initial CNS insult, ongoing inflammation may alter neuronal plasticity with network reorganization through several transcriptionally regulated effects, with potential for aberrant and epileptogenic circuits. [14] [15] [16] [17] [18] Activation of the pathway enhances the permeability of an already dysfunctional blood-brain barrier, allowing for movement and detection of these proteins into the peripheral circulation, raising the possibility of their utility as a biomarker of disease. 19, 20 In this study, we aimed to determine whether the levels of cytokines in neonates with brain injury are associated with acute symptomatic seizures and the development of epilepsy in childhood. We hypothesize that changes in a diffuse set of neonatal cytokines will be associated with acute seizures, though only increases in cytokines within the pro-inflammatory IL-1β pathway will be associated with remote epilepsy.
METHODS

Subjects
This is a nested cohort study within a longitudinal investigation of term and near-term newborns at risk of neonatal encephalopathy. 21, 22 As previously reported, newborns were recruited who were admitted to the Intensive Care Nursery at UCSF and a nearby county hospital between 10/1993 and 1/2000 and had any of the following: (1) umbilical artery pH <7.1, (2) umbilical artery base deficit >10, (3) Apgar score ≤5 at 5 min of life, or (4) overt neonatal encephalopathy as assessed by a neonatologist. This cohort was assembled before the adoption of therapeutic hypothermia. Neonates were excluded if there was evidence of major congenital malformations, congenital metabolic diseases, or perinatal or intrauterine infection. The original cohort enrolled 125 neonates, 62 of which had cytokine levels evaluated from dried blood spots. Here we aimed to evaluate cytokine levels in term neonates with high risk of brain injury. We applied additional exclusion criteria to the study base, excluding neonates <37 weeks gestational age, without both clinical and physiologic evidence of hypoxia-ischemia (and therefore not meeting our institutional therapeutic hypothermia criteria), 23 deceased during the birth admission, and dried blood spots collected < 24 or >120 h after birth to allow for evaluation of relevant cytokines at peak levels after an acute neurologic injury. 21, 24, 25 Epilepsy classification was restricted to those with at least 2 years of follow-up to allow for the development of epilepsy. 3, 4] Measurements Cytokines. Cytokine levels were previously evaluated, and levels were reported in an investigation evaluating their association with magnetic resonance spectroscopy (MRS) and development. 21 In brief, dried blood spots were obtained from heel-stick blood as a part of California's newborn screening program. Dried blood spots were analyzed by recycling immunoaffinity chromatography. 26 Twenty-five-microliter samples were injected into serially connected microcolumns, each containing a different immobilized capture antibody interleukin (IL)-1, IL-6, IL-8, IL-9, IL-12, IL-13, and tumor necrosis factor (TNF)-α). 22 Analytes were released by treatment with acidic buffer and measured by laser-induced fluorescence.
Clinical data. Trained research assistants prospectively abstracted demographics and birth delivery data. 21 Encephalopathy scores were determined by expert review. 21, 22 Magnetic resonance imaging (MRI) injury scores were determined by combining scores for abnormalities in the deep gray nuclei and white matter. 27 Two authors (A.L.N., H.C.G.) reviewed charts for encephalopathy etiology, presence of clinical and/or electrographic neonatal acute symptomatic seizures, and epilepsy as defined by the International League Against Epilepsy 2014 criteria. 28 Data analysis. Analyses were performed using the Stata 15.1 software (Stata Corp, College Station, TX). Chi-square test was used to compare categorical variables, Whitney Rank-Sum test was used to compare ordinal variables, and t test was used to compare continuous variables with acute seizures or epilepsy. For the analyses of cytokines, linear regression was used to compare levels with continuous variables, Kruskal-Wallis test was used with ordinal variables, and t tests or analysis of variance were used for comparisons of categorical predictors and outcome variables. We performed validation using sensitivity analyses with nonparametric tests. The area under the receiver operator curve (AUC) for cytokine levels and epilepsy were estimated using non-parametric methods.
Rv3.2.0 (R Foundation for Statistical Computing, Vienna, Austria) was used for clustering methods, using the gplots package. For each patient, cytokine values were scaled by subtracting the mean cytokine value across all patients from each particular patient cytokine level. This value was then divided by the standard deviation of the particular cytokine. Hierarchical agglomerative clustering algorithms were used to evaluate clusters of patients within the plasma cytokine determinants. Data were standardized as Z-scores by subtracting mean and divided by standard deviation for each cytokine. Pearson's correlation similarity metric and Ward linkage function were used for hierarchical agglomerative cluster analysis. For each clustering algorithm, dendrograms, heatmaps, and bubblemaps were created to visualize the clusters and scaled cytokine values. Dark blue colors on the heatmaps represent low cytokine values, white colors represent average values, and red represent high values. Larger bubbles on bubblemaps correspond to higher cytokine values.
The protocol was approved by the Committee for Human Research at the University of California, San Francisco and voluntary informed consent was obtained from parents or legal guardians.
RESULTS
Cohort characteristics
From a study base of 62 neonates with encephalopathy, we excluded 7 (11%) neonates < 37 weeks gestational age, 10 (16%) infants without clinical and physiologic evidence of hypoxia-ischemia, 2 (3%) deceased during the birth admission, and 10 (16%) infants with dried blood spots collected <24 or >120 h after birth. Seven (11%) of the 62 infants had missing clinical details on birth history and follow-up, leaving 26 infants for evaluation of acute symptomatic seizures. Among these 26 infants, 22 (85%) had radiologic evidence consistent with hypoxia-ischemia, 3 (12%) had radiologic evidence of ischemic or hemorrhagic stroke, and 1 (4%) had laboratory-confirmed meningitis.
Acute seizures Fifteen (58%) of the 26 neonates had acute symptomatic seizures. Seizure onset was within 48 h of life in all subjects. Five neonates had rare (<7) seizures, 2 had frequent recurrent seizures (≥7), and 2 had status epilepticus. The remaining 6 had greater than 1 seizure, but the precise burden could not be determined by chart review. Neonates with acute seizures had higher encephalopathy scores and a trend for higher MRI injury scores compared to those without acute seizures ( Table 1 ). The groups did not differ on other demographic, clinical, and maternal risk factors.
Remote epilepsy Seventeen (65%) of 26 neonates had >2 years of follow-up data for review to evaluate epilepsy onset after the neonatal period. Four of the 17 (24%) developed epilepsy, all of whom had a history of acute symptomatic seizures. There were no significant differences in demographic, clinical, and maternal risk factors between those with and without remote epilepsy (Table 1) .
Cytokine analyses
Cytokine levels were evaluated at 2.5 days of life (95% confidence interval: 2.1-2.9). There were no significant differences in timing of DBS collection between those with and without acute symptomatic seizure or between those with and without remote epilepsy. Cytokine levels did not vary by sex, race, gestational age, maternal age, encephalopathy etiology, encephalopathy score, or MRI severity score.
Neonates with acute symptomatic seizures had broad difference in cytokines levels in comparison to those without acute seizures (Fig. 1) . Those with acute seizures had higher levels of IL-1, -6, -8, -9, -13, and TNF-α, as well as lower levels of IL-12, compared to those without acute seizures. In contrast, neonates who developed epilepsy had higher levels of cytokines specific to the IL-1β pathway, including IL-6 and TNF-α, as well as IL-9 (Fig. 2 ). There was trend for higher IL-1 levels (combined α and β subunits) in those who developed epilepsy (p = 0.07).
We evaluated whether cytokine levels can discriminate between those with and without remote epilepsy with the receiver operator curve characteristics. The AUC for cytokines within the pro-inflammatory IL-1β pathway ranged from 0.87 to 0.88, demonstrating a strong effect and superior performance to IL-12 and IL-13 (Table 2 ). Hierarchical agglomerative clustering algorithms revealed difference in patterns of cytokine level changes in neonates with and without later onset of epilepsy ( Fig. 3) . Dendrograms (Fig. 3 ) and bubblemaps/heatmaps (Fig. 4) confirmed correlations of cytokines within the pro-inflammatory IL-1β pathway (IL-1, IL-6, IL-8, TNF-α). IL-12 and IL-13, which are involved in disparate signaling pathways, were not correlated with the other cytokines measured.
DISCUSSION
Here we evaluated the association of inflammatory cytokines with acute symptomatic seizures and development of remote epilepsy in a cohort of neonates with encephalopathy. Acute symptomatic seizures in neonates with encephalopathy were associated with broad changes in cytokines in both pro-and antiinflammatory cytokine levels. However, only increased levels of pro-inflammatory cytokines in the IL-1β pathway, and to a lesser extent, IL-9 were associated with later development of epilepsy.
This group previously reported that, in this cohort of neonates with encephalopathy, elevations in IL-1, IL-6, and IL-8 on dried blood spots were correlated with elevated lactate peaks on MRS. 21 Early changes in pro-inflammatory cytokine levels in neonates with. . . AL Numis et al. Similarly, "The Extremely Low Gestational Age Newborn Study" (ELGAN) study evaluated several cytokines in premature infants born <28 weeks gestation using analyses of dried blood spots. 25 Changes in cytokine levels in several pro-and anti-inflammatory pathways were associated with the presence of intraventricular hemorrhage and/or white matter injury. 29 As neonatal brain injury is a risk factor for the development of acute symptomatic seizures, 3, 4 it is not surprising that we found acute symptomatic seizures after neonatal brain injury were associated with alterations in a number of pro-and anti-inflammatory cytokine pathways. Our findings corroborate data from a cohort of 13 neonates with hypoxic-ischemic encephalopathy, where serum levels of IL-1 receptor antagonist (IL-1RA; an inhibitor of the IL-1 pathway) were lower and levels of IL-8 were higher among neonates with seizures compared to controls, 24 though, in all clinical studies evaluating cytokines levels in neonates to date, the development of remote epilepsy was not assessed. Our finding that neonatal elevations of cytokines within the IL-1β pathway are associated with the development of epilepsy in childhood is novel. This pathway, however, has been associated with epilepsy in several other clinical populations, including adults with traumatic brain injury and post-traumatic epilepsy. 30, 31 Therefore, this pathway may serve as a marker of epilepsy across several types of brain injury with the potential for understanding mechanisms of epileptogenesis. 32 Cytokines in the IL-1β pathway modulate the excitatory NMDA receptor and the inhibitory GABA receptor on neurons and astrocytes, resulting in lower seizure thresholds, which can lead to a positive feedback loop with perpetuation of seizure activity and brain inflammation. [11] [12] [13] 33, 34 After an initial brain injury, this ongoing inflammation can alter neuronal plasticity with network reorganization through several transcriptionally regulated effects, with potential for aberrant and epileptogenic circuits. [14] [15] [16] [17] [18] In addition to differences in the IL-1β pathway, we also found that increased levels of IL-9 were associated with later development of epilepsy. The role of IL-9 in neurologic injury is less understood, with an emerging role in encephalomyelitis and multiple sclerosis. 35 Further investigations are needed to validate this finding.
Limitations of our study include our small sample size, which did not allow us to evaluate for potential confounding by brain injury severity on cytokine levels and later development of epilepsy. The etiology of neonatal encephalopathy, however, was similar to that observed in larger cohorts of term neonates. While the prevalence of acute symptomatic seizures in neonates with encephalopathy is higher than that of contemporary cohorts (58%), it is consistent with the prevalence of acute symptomatic seizures in neonates before therapeutic hypothermia was adopted. 36 In this cohort, the evaluation of acute symptomatic seizures was not standardized. During the time period in which the cohort was assembled, EEG was not consistently used to evaluate for subclinical seizures in the neonatal period. While this could result in misclassification of neonates without "acute symptomatic seizure," this would reduce our ability to detect an association of cytokine levels with seizures. The prevalence of epilepsy (24%) in this cohort is similar to that observed in larger cohort studies. 37 Owing to the retrospective cohort design, several patients were lost to follow-up for evaluation of epilepsy. While this could introduce bias, we anticipate that cases of epilepsy were unlikely to be misclassified owing to referral patterns within our catchment area.
Here we used dried blood spots to measure cytokine levels. This sampling results in increased measurement variability compared to measurement of cytokine levels in serum or plasma likely owing to the use of capillary blood, sample spread, and activity of leukocytes during sample storage without early centrifugation. 38, 39 We would anticipate the use of serum or plasma would decrease the spread of cytokine levels by group and therefore strengthen the observed associations. Here measurement of IL-1 levels included both the IL-1α and β subunits. The IL-1β subunit is responsible for inflammation after a neurologic injury, whereas the α subunit is largely skin derived and would not be expected to change after brain injury. 40 Levels of IL-1α and IL-1β are similar in circulation; therefore inclusion of IL-1α in measurements would dilute the association of IL-1β with our outcomes. If subunit composition analysis of IL-1β were possible, we hypothesize that the trend for increased IL-1 levels associated with epilepsy would have a larger effect size and become statistically significant.
Our findings support the utility of circulating cytokines as a predictor of epilepsy after neonatal brain injury. Larger, prospective studies in contemporary cohorts of neonates are necessary to validate these findings and evaluate for interactions between changes in cytokines levels and the IL-1β pathway with clinical factors known to increase risk of remote epilepsy such as brain injury and acute seizure severity. 
